Characterization of GDF2 Mutations and Levels of BMP9 and BMP10 in Pulmonary Arterial Hypertension.
暂无分享,去创建一个
W. Ouwehand | M. Humbert | W. Seeger | I. Prokopenko | P. Corris | M. Haimel | M. Bleda | H. Ghofrani | S. Gräf | R. Trembath | S. Holden | S. Ghio | L. Daugherty | N. Morrell | Jingxu Guo | B. Girerd | D. Montani | M. Eyries | F. Soubrier | J. Wharton | M. Wilkins | H. Gall | L. Scelsi | D. Kiely | H. Olschewski | C. Rhodes | E. Swietlik | Jennifer M. Martin | K. Yates | H. Bogaard | R. Condliffe | G. Kovacs | A. Olschewski | L. Howard | J. Gibbs | C. Danesino | Wei Li | R. Machado | A. Vonk Noordegraaf | P. Yu | S. Wort | L. Southgate | C. Hadinnapola | J. Hodgson | R. Salmon | C. Treacy | O. Shamardina | C. Church | G. Coghlan | A. Houweling | Robert V MacKenzie Ross | S. Moledina | A. Peacock | J. Pepke-Żaba | J. Suntharalingam | M. Toshner | A. Lawrie | P. Upton | J. Liley | Katherine P. Yates | I. Nikolic | Deborah Whitehorn | Jennifer M Martin | J. Pepke-Zaba
[1] C. Huard,et al. Bone Morphogenetic Protein 9 Is a Mechanistic Biomarker of Portopulmonary Hypertension , 2019, American journal of respiratory and critical care medicine.
[2] M. Humbert,et al. Selective BMP-9 Inhibition Partially Protects Against Experimental Pulmonary Hypertension , 2019, Circulation research.
[3] W. Chung,et al. Genetics and genomics of pulmonary arterial hypertension , 2019, European Respiratory Journal.
[4] M. Humbert,et al. Widening the landscape of heritable pulmonary hypertension mutations in paediatric and adult cases , 2019, European Respiratory Journal.
[5] Y. Mao,et al. Germline BMP9 mutation causes idiopathic pulmonary arterial hypertension , 2019, European Respiratory Journal.
[6] M. Haimel,et al. S41 Characterisation of mutations in the gene encoding growth and differentiation factor 2 (GDF2) in patients with pulmonary arterial hypertension , 2018, Fundamental mechanisms of pulmonary arterial hypertension.
[7] M. Humbert,et al. S40 Phenotypic characterisation of GDF2 mutation carriers in a large cohort of patients with pulmonary arterial hypertension , 2018, Fundamental mechanisms of pulmonary arterial hypertension.
[8] Agnès Desroches-Castan,et al. A heterodimer formed by bone morphogenetic protein 9 (BMP9) and BMP10 provides most BMP biological activity in plasma , 2018, The Journal of Biological Chemistry.
[9] Henning Gall,et al. Identification of rare sequence variation underlying heritable pulmonary arterial hypertension , 2018, Nature Communications.
[10] S. Archer,et al. Pulmonary arterial hypertension: pathogenesis and clinical management , 2018, British Medical Journal.
[11] P. Corris,et al. Plasma Metabolomics Implicates Modified Transfer RNAs and Altered Bioenergetics in the Outcomes of Pulmonary Arterial Hypertension , 2017, Circulation.
[12] Stephen Kaptoge,et al. BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis , 2016, The Lancet. Respiratory medicine.
[13] D. Penny,et al. Novel homozygous BMP9 nonsense mutation causes pulmonary arterial hypertension: a case report , 2016, BMC Pulmonary Medicine.
[14] N. Morrell,et al. Generation and Culture of Blood Outgrowth Endothelial Cells from Human Peripheral Blood , 2015, Journal of visualized experiments : JoVE.
[15] Wei Li,et al. The Prodomain-bound Form of Bone Morphogenetic Protein 10 Is Biologically Active on Endothelial Cells , 2015, The Journal of Biological Chemistry.
[16] M. Humbert,et al. Pulmonary Arterial Hypertension: A Current Perspective on Established and Emerging Molecular Genetic Defects , 2015, Human mutation.
[17] E. Chao,et al. Mutations in RASA1 and GDF2 identified in patients with clinical features of hereditary hemorrhagic telangiectasia , 2015, Human Genome Variation.
[18] S. Gräf,et al. Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension , 2015, Nature Medicine.
[19] R. Schermuly,et al. [Relevant issues in the pathology and pathobiology of pulmonary hypertension]. , 2014, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.
[20] N. Morrell,et al. Regulation of Bone Morphogenetic Protein 9 (BMP9) by Redox-dependent Proteolysis* , 2014, The Journal of Biological Chemistry.
[21] J. Skepper,et al. Transcript Analysis Reveals a Specific HOX Signature Associated with Positional Identity of Human Endothelial Cells , 2014, PloS one.
[22] J. Shendure,et al. A general framework for estimating the relative pathogenicity of human genetic variants , 2014, Nature Genetics.
[23] Nicholas W Morrell,et al. Relevant issues in the pathology and pathobiology of pulmonary hypertension. , 2013, Journal of the American College of Cardiology.
[24] Brendan D. O'Fallon,et al. BMP9 mutations cause a vascular-anomaly syndrome with phenotypic overlap with hereditary hemorrhagic telangiectasia. , 2013, American journal of human genetics.
[25] W. Chung,et al. A novel channelopathy in pulmonary arterial hypertension. , 2013, The New England journal of medicine.
[26] W. Chung,et al. Genetics and genomics of pulmonary arterial hypertension. , 2013, Journal of the American College of Cardiology.
[27] W. Chung,et al. A novel channelopathy in pulmonary arterial hypertension. , 2013, The New England journal of medicine.
[28] W. Chung,et al. Whole Exome Sequencing to Identify a Novel Gene (Caveolin-1) Associated With Human Pulmonary Arterial Hypertension , 2012, Circulation. Cardiovascular genetics.
[29] L. David,et al. BMP9 is produced by hepatocytes and circulates mainly in an active mature form complexed to its prodomain , 2012, Cellular and molecular life sciences : CMLS.
[30] L. David,et al. BMP9 is produced by hepatocytes and circulates mainly in an active mature form complexed to its prodomain , 2011, Cellular and Molecular Life Sciences.
[31] P. Bork,et al. A method and server for predicting damaging missense mutations , 2010, Nature Methods.
[32] W. Chung,et al. [Genetics and genomics of pulmonary arterial hypertension]. , 2014, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.
[33] L. David,et al. Bone Morphogenetic Protein-9 Is a Circulating Vascular Quiescence Factor , 2008, Circulation research.
[34] L. David,et al. Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. , 2007, Blood.
[35] J. Loscalzo,et al. Pulmonary arterial hypertension. , 2004, Annals of medicine.
[36] S. Batzoglou,et al. Distribution and intensity of constraint in mammalian genomic sequence. , 2005, Genome research.
[37] P. ten Dijke,et al. Identification and Functional Characterization of Distinct Critically Important Bone Morphogenetic Protein-specific Response Elements in the Id1 Promoter* , 2002, The Journal of Biological Chemistry.
[38] M. Humbert,et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. , 2001, The New England journal of medicine.
[39] S. Henikoff,et al. Predicting deleterious amino acid substitutions. , 2001, Genome research.
[40] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .